Product Description
Mechanisms of Action: SP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Korea | Taiwan | Ukraine
Approved Indications: None
Known Adverse Events: None
Company: Yonsei University
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Sepsis|Hepatocellular Carcinoma|Reperfusion Injury|Small Cell Carcinoma|Liver Failure, Acute
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR-IPR-14005518 |
ChiCTR-IPR-14005518 | N/A |
Not yet recruiting |
Pancreatitis, Acute |
2017-12-31 |
|||
NCT02710266 |
NCT02710266 | P3 |
Terminated |
Reperfusion Injury|Liver Failure, Acute|Small Cell Carcinoma|Sepsis|Hepatocellular Carcinoma |
2017-02-25 |
2019-03-20 |
Treatments |